Medicine is being increasingly driven by data. Advances in genomic sequencing, wearable devices for data collection, biomarker discoveries, and machine learning are enabling care teams to personalize treatment not just by disease type, but also by individual patient. This move from population-based medicine to personalized care is significantly improving cancer treatment.

Traditionally, chemotherapy takes somewhat of a broad approach, but precision medicine provides a more nuanced and strategic treatment plan. Instead of attacking all rapidly dividing cells, today’s most promising therapies intercept the genetic mutations, regulatory pathways, and cellular dependencies that drive tumor growth in specific patient subtypes. 

Companies like Prelude Therapeutics are leveraging genetic data to develop next-generation, small-molecule, targeted therapies that are more akin to a scalpel than a sledgehammer. Rather than chasing crowded targets or broad labels, Prelude’s pipeline focuses on unaddressed genomic drivers and mechanisms of resistance in difficult-to-treat cancers. These include PRT2527, a CDK9 inhibitor; PRT3645, a selective CDK4/6 inhibitor; and PRT3789, an oral SMARCA2 degrader aimed at tumors with SMARCA4 loss. 

At the head of this strategy is Dr. Jane Huang, the President and Chief Medical Officer of Prelude Therapeutics. Before joining Prelude in 2022, Dr. Jane Huang had accumulated over 20 years of experience in hematology and oncology drug development. Her career spanned academic medicine, global biotech, and clinical development leadership at companies like Genentech, Acerta Pharma, and BeiGene. 

Dr. Huang began her career as a practicing hematologist and oncologist and is also board-certified in internal medicine. Her clinical experience grounds her approach to drug development in the real-world challenges and nuances of patient care, which continues to define her leadership approach. 

At Genentech, Dr. Huang helped advance flagship oncology products through all phases of development. She contributed to pivotal programs for Rituxan®, Avastin®, Kadcyla®, Venclexta®, and Gazyva®, gaining a reputation as a cross-functional leader with a talent for integrating clinical strategy with regulatory and commercial imperatives.

In her next role as Vice President of Clinical Development at Acerta Pharma, she oversaw the global clinical development of the BTK inhibitor acalabrutinib, a molecule that would eventually become AstraZeneca’s Calquence. 

At BeiGene, where she served as Chief Medical Officer of Hematology, she built a global development organization from the ground up. Under her leadership, the company achieved regulatory approvals for zanubrutinib across more than 45 countries in three indications, and she led the development of tislelizumab, an anti-PD-1 antibody that became the first such agent approved for Hodgkin’s lymphoma in China.

At Prelude, Dr. Huang drives the company’s current trials as well as its long-term strategic direction, from biomarker strategy and clinical operations to regulatory planning and global development readiness.

Looking Ahead

With Dr. Jane Huang leading clinical strategy, Prelude is shifting from hypothesis to validation. Much of that momentum centers on PRT2527, the company’s selective CDK9 inhibitor, which is being evaluated in patients with relapsed or refractory lymphoid malignancies.

In late 2024, Prelude presented early clinical data that showed meaningful responses in heavily pretreated patients with lymphoid malignancies. These results are critical proof of the ability to selectively shut down key oncogenic pathways and drive response in genomically defined subpopulations. 

The company is now entering a phase of acceleration: expanding trials, refining patient selection strategies, and positioning its lead assets for broader evaluation.

Looking ahead, Prelude’s programs targeting SMARCA2 loss and CDK4/6 inhibition are entering a maturation phase. With early human data now validating several mechanisms, the company is preparing to move on from exploratory studies to potential registrational pathways. This is a defining moment for Prelude because they are no longer proving their science, they are preparing to translate it into practice.

As big pharma continues to retreat from niche or mechanistically complex conditions, Prelude is picking up the slack with the clarity, data, and translational focus needed to serve them. We hope Prelude’s next phase will bring targeted therapies to patients who have few existing options.